SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ore Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (29)5/15/2009 10:55:46 AM
From: Mike McFarlandRead Replies (1) | Respond to of 50
 
At March 31st, $7M cash, no first quarter revenue

ORE1001
ORE5002 (tiapamil)
ORE5007 (romazarit)

discontinued drug repositioning program

Next quarter burns half the cash then the
last bit of sand runs out of the clock over
the second half of the year
The Company also expects its cash usage for
the second half of 2009 to be significantly lower
than the first half.

So imo, a buyer soon--but either way this
goes out with but a whimper.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News